What Obex-LA Treats: Main Uses and Benefits

Obex-LA (Phendimetrazine) is commonly used to help with the short-term management of exogenous obesity in adult patients who meet specific clinical criteria. The use is relevant in conditions characterized by periods of heightened symptoms when a patient has a Body Mass Index (BMI) of 30 kg/ m^2 or greater, or a BMI of 27 kg/ m^2 or greater when coupled with other weight-related health issues. The medication's role is to contribute to supportive relief during the initial phase of weight reduction, always functioning as an adjunctive measure and providing support that helps ease the overall symptom burden when coupled with a medically prescribed regimen of diet and exercise.

---

The drug is applied in addressing the symptom clusters of persistent, excessive hunger. By providing supportive symptomatic relief through appetite suppression, it helps ease the physical and mental discomfort associated with maintaining a reduced-calorie diet.

“This supportive function may assist with maintaining functional stability by helping patients cope more steadily with dietary adherence.”

This contributes to improved comfort during periods of heightened symptoms related to adopting new eating behaviors.

---

Quick Fact: Supportive Relief for Excessive Hunger

Property	Description
Primary Indication	Short-term management of exogenous obesity
Symptom Managed	Persistent, excessive hunger sensations
Therapeutic Role	Adjunctive support for initial weight reduction
Patient Benefit	Assists with maintaining functional stability

Regulatory References

1. PHENDIMETRAZINE TARTRATE tablet - DailyMed - NIH

This section summarizes the official population eligibility and exclusion criteria for Obex-LA, based strictly on regulatory documentation for this class of medication.

Eligibility Criteria

Allowed Populations (Based on BMI)

Use is restricted to adults who are managing exogenous obesity as a short-term adjunct to diet and exercise. Eligibility requires an initial Body Mass Index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater if a weight-related comorbidity (such as controlled hypertension or diabetes) is present.

Age-Group Rules

• Pediatric Patients: Safety and effectiveness have not been established in children under the age of 17 years, and use is generally not recommended.
• Geriatric Patients (65+): Use requires caution and monitoring due to the greater frequency of age-related organ function decline.

Contraindications and Exclusions

Use of Obex-LA is formally contraindicated (must not be used) in patients with the following conditions or states:

• Cardiovascular Disease: History of coronary artery disease, stroke, arrhythmias, congestive heart failure, or uncontrolled hypertension.
• Other Conditions: Hyperthyroidism, glaucoma, agitated states, and a history of drug abuse.
• Drug Interactions: During or within 14 days following the administration of Monoamine Oxidase Inhibitors (MAOIs).
• Physiological States: Pregnancy and nursing (breastfeeding).

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Obex-LA (Phendimetrazine tartrate) as established by government regulatory agencies.

Substances Prohibited for Co-Administration

Regulatory agencies classify several drug combinations with Obex-LA as contraindicated due to interaction risk:

• Monoamine Oxidase Inhibitors (MAOIs): Use is prohibited during or within 14 days following the administration of an MAOI to avoid the potential for hypertensive crisis.
• Other Anorectic Agents: This includes prescription, over-the-counter, and herbal preparations with appetite-suppressing effects. Co-administration is prohibited due to the potential for serious cardiac problems.
• Other Central Nervous System (CNS) Stimulants: Combination with other stimulants is also prohibited.

Pharmacodynamic and Clearance Considerations

Interactions documented in the official labeling involve changes to existing medication effectiveness or drug clearance:

• Antidiabetic Medications: Requirements for Insulin and other oral hypoglycemic medications may be altered in patients with diabetes due to the required dietary regimen accompanying Obex-LA use.
• Adrenergic Neuron Blocking Drugs (e.g., Guanethidine): Co-administration may decrease the hypotensive effect of these blood pressure-regulating drugs.
• Alcohol: Concomitant use with alcohol is noted to potentially result in an adverse drug reaction.
• Renal Impairment: Patients with impaired renal function may have a greater risk of toxic reactions as the drug is cleared more slowly, leading to increased systemic exposure.

Central Monoamine Transporter Modulation

Obex-LA’s mechanism of action involves the modulation of monoamine transporters in the central nervous system. Its active compound, phenmetrazine, functions as an indirect sympathomimetic amine. This interaction increases the concentration of the neurotransmitters norepinephrine and dopamine in the synaptic cleft by both stimulating their release from presynaptic neurons and inhibiting their reuptake back into the nerve cell.

---

Hypothalamic Appetite Regulation

The elevated availability of monoamines primarily targets the hypothalamic feeding centers, which regulate the perception of hunger and satiety. By enhancing sympathetic signaling in the hypothalamus, the mechanism modifies the balance between satiety and hunger signals, leading to an anorexigenic effect (reduction of appetite). This modulation of appetite signaling is a primary physiological consequence that alters food intake.

---

Systemic Sympathetic Activation

Beyond the brain’s control centers, the mechanism causes a generalized increase in sympathetic (adrenergic) activity across the body. This systemic effect leads to a modest increase in heart rate, blood pressure, and metabolic rate, contributing to the overall physiological changes produced by the mechanism.

Official Administration Guidelines for Obex-LA

Note on Available Information: As of the latest review, there is no public safety and efficacy review or approved prescribing information specifically for a pharmaceutical product named Obex-LA. Consequently, no official instructions regarding its administration, dosage, or preparation exist in public databases.

---

Administration Requirements

Classification	Information for Obex-LA
Route of administration	Not specified in official documents.
Official dosing schedule	No defined or approved dosage is published.
Timing in relation to meals	Not specified in official documents.
Preparation requirements	No instructions for dilution, reconstitution, or shaking are officially documented.
Age-group administration rules	No age-specific rules or restrictions are published.
Missed-dose rules	No official instructions for managing a missed dose are published.

---

Procedural Structure

Due to the absence of an approved label, a formal, step-by-step procedure for the use of Obex-LA cannot be constructed based on mandatory documentation. Information on potential anti-obesity activity of a substance named OBEX has been documented in research, but this research does not constitute official administration guidelines.

Basis of Information: This section is structured to present only the information that would be found in a formal product label. The current finding is that such a document for a product named Obex-LA is not publicly available.

Research evidence / Overview of studies for Obex-LA

---

Evidence Base for Short-Term Use in Exogenous Obesity (BMI ge 30 kg/ m^2)

Research examining Obex-LA (Phendimetrazine) has primarily focused on its use as adjunctive therapy (a supportive addition) alongside a medically supervised regimen of diet and increased physical activity. The evidence base for this use largely relies on short-term Randomized Controlled Trials (RCTs). These studies were evaluated in adults who met the criteria for obesity. Researchers primarily monitored changes in mean body weight and the proportion of participants who reached specific short-term weight loss goals over defined periods, typically up to 12 weeks.

Findings describe patterns observed as studies explored whether the group receiving Phendimetrazine was associated with specific changes in measured body weight when compared to the group receiving a placebo. Research highlights changes measured during this specific study period, which help contextualize how patients reported their experience with appetite control.

---

Duration of Evidence: Short-Term Focus and Long-Term Gaps

The evidence base for Phendimetrazine is characterized by a strong focus on short-term outcomes. The pivotal trials were generally limited to maximum treatment periods of around 12 weeks. This means the research provides insight into short-term changes, but there is limited information for long-term outcomes regarding the use of Obex-LA.

The longer-term effects are not fully established. There is a lack of high-quality studies that have monitored patients for extended periods (e.g., years) to determine if any measured weight change is sustained after the medication is discontinued. Furthermore, evidence suggests that tolerance to the appetite-suppressing effect may develop after a few weeks of continuous use, and long-term effects are not fully established.

---

Status of Evidence in Special Populations

Research has not sufficiently established the safety and effectiveness of Phendimetrazine in several important special populations. Data for certain groups remain insufficient, and the results apply only to the populations studied. For example, for pediatric patients (under 17 years old), the safety and effectiveness were not evaluated in dedicated studies. Similarly, research has not conducted specific studies on drug exposure in patients with renal (kidney) impairment, meaning data for certain groups remain insufficient regarding drug exposure or risk profiles.

Key Studies & References Label: PHENDIMETRAZINE TARTRATE ER and Tablet (DailyMed - NIH)

Common questions about Obex-LA (FAQ)

---

Q: How long does it usually take to notice what Obex-LA is doing?

Pharmacokinetic studies indicate that the active compound reaches its highest concentration in the bloodstream (peak blood levels) generally between one and three hours after a dose is taken. This time frame is understood to be the point where the concentration of the active ingredient is highest.

---

Q: If I miss a day of Obex-LA, what happens?

Official guidelines describe that if a dose is missed, it can be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped. The instructions strictly state that doses should never be doubled.

---

Q: Can you take Obex-LA if you have high blood pressure?

According to official product labeling, this medicine is contraindicated, or forbidden, for individuals with moderate and severe high blood pressure (hypertension). Official labeling indicates that caution is advised when the medicine is considered for patients with mild hypertension.

---

Q: Are there any common foods or drinks that interfere with Obex-LA?

Regulatory documents strictly prohibit concurrent use of this medicine with alcohol, as this may result in an adverse reaction. While no specific foods are listed as interfering, official guidelines describe the medicine’s use as always being alongside a prescribed, reduced-calorie diet.

---

Q: How does Obex-LA interact with common cold or allergy medications?

Regulatory information states that combining this medicine with other sympathomimetic agents, which are often present in common cold or allergy medications (e.g., pseudoephedrine), is prohibited. This restriction is in place because the combination can increase the risk of serious side effects, such as elevated heart rate and blood pressure.

---

Q: Does Obex-LA affect fertility or hormones?

Official product information indicates that specific studies to evaluate the drug's effects on fertility have not been performed. Due to the lack of specific studies, information on this topic is not available in authoritative regulatory documents.

---

Q: Does Obex-LA require any special kind of monitoring by a doctor?

Official recommendations describe that regular patient monitoring is customary during use. This typically includes assessing vital signs like blood pressure and heart rate, tracking body weight changes, and evaluating the patient for potential side effects or signs of drug dependence.

---

Q: Is Obex-LA related to any older weight management drugs?

According to official sources, the active compound phendimetrazine is chemically related to the older compound phenmetrazine. Phendimetrazine is classified as a prodrug, meaning it acts as a precursor to this related compound.

---

Q: What does 'contraindication' mean in the context of Obex-LA?

A contraindication is a specific medical condition or situation where the use of a medicine is forbidden because it could potentially cause harm to the patient. This means the medicine should not be used when that condition is present, as it may cause harm.

---

Q: Does Obex-LA have a high risk warning or 'Black Box' warning?

Official regulatory documents contain prominent WARNINGS regarding the potential for serious and potentially life-threatening cardiovascular and pulmonary events. The warnings highlight serious risks, such as primary pulmonary hypertension (PPH) and damage to the heart valves, which are prominently noted in the official labeling.

---

Q: Is Obex-LA considered a first-line treatment option?

Official documents state the medicine is indicated for use only as a short-term adjunct (a supporting addition) to a comprehensive weight-reduction plan. It is not indicated as the sole treatment for obesity.

---

Q: Is there a generic version of Obex-LA available?

Yes, the active ingredient in this medicine is available as a generic drug. Generic forms are supplied in various strengths and physical forms, such as tablets and extended-release capsules.

---

Q: Are there any vitamins or herbal supplements that are known to interact with Obex-LA?

Official warnings state that this medicine should not be combined with any other appetite-suppressing agents, including prescription drugs, over-the-counter products, or herbal supplements. The official documents do not specifically address interactions with standard vitamins that do not have an appetite-reducing effect.

---

Q: Can Obex-LA change your mood or cause anxiety?

Regulatory sources list nervousness as a commonly reported adverse reaction. Furthermore, official labeling indicates that the medicine is contraindicated (forbidden) for individuals who are in highly nervous or agitated states, which covers certain extreme mood and anxiety symptoms.

---

Q: Do researchers know exactly how Obex-LA works on the brain?

Official pharmacological information describes the mechanism as stimulating the central nervous system to decrease appetite. While this action is clear, authoritative sources indicate that the precise way this class of drugs leads to weight reduction is not fully established in research.

---

Q: Are there different strengths or doses of Obex-LA?

Yes, the active ingredient in this medicine is manufactured in various strengths and is available in different physical forms, such as immediate-release tablets and extended-release capsules.

---

Q: What happens if Obex-LA is taken too close to bedtime?

Official product information indicates that taking this medicine too late in the day may cause trouble sleeping, or insomnia, which is listed as a common side effect. This effect is managed by careful consideration of the dose timing.

---

Q: Does Obex-LA interact with thyroid medication?

Regulatory documents state that use of this medicine is contraindicated (forbidden) in patients with the condition Hyperthyroidism (overactive thyroid) due to the potential for serious cardiovascular effects. While the interaction with the medication itself is not explicitly listed, the contraindication for the underlying condition is clearly stated.

How to Store and Dispose of Obex-LA?

The storage and disposal of Obex-LA (Phendimetrazine) are strictly governed by its official regulatory status.

Storage Requirements

Obex-LA must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F), in a tight container to protect from moisture. As a controlled substance, the medication must be stored in a safe place to prevent theft and kept out of the reach of children and pets.

---

Disposal Instructions

Unused or expired Obex-LA must be disposed of promptly. The preferred method is using a drug take-back program. If this is unavailable, the alternative is to mix the product with an unappealing substance (like dirt or coffee grounds), seal it in a bag, and discard it in the household trash. This prevents accidental exposure and misuse.